TrialDiabetes, obesity & metabolism2014

Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.

M J Davies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.